Article Sidebar

Submitted
16 May 2021
Accepted
24 January 2022
Published
7 March 2022
Download
PDF
Statistic
Read Counter : 702 Download : 459

Main Article Content

Abstract

Hightlight:

  1. The effect of orlistat on glycemic control and weight loss in overweight or obese type 2 diabetes mellitus patients was determined

  2. HbA1c and FPG level in overweight and obese type 2 diabetes mellitus patient can improved by orlistat as an adjuvant therapy.

 

Abstract:

Risk of Type 2 diabetes mellitus (T2DM) increases steadily with increasing overweight and obesity, and these two-health problems are emerging epidemics worldwide. Orlistat, a lipase inhibitor for weight loss drug, is often used in T2DM medication as adjuvant therapy, but effectiveness of the drug for improving glycemic control on T2DM patients is unclear. This study was to determine the effect of orlistat on glycemic control and weight loss in overweight or obese patients with T2DM. Term “Orlistat” AND “(obesity OR overweight)” AND “(HbA1c OR A1C)” AND “diabetes” were systematically searched in Pubmed and Science Direct web databases up to March 2021. Only randomized controlled study (RCT) methods studies were included in this study. Collected final samples were presented in a table with narrative review. There were 9 RCT studies with a total 2,175 subjects that met inclusion criteria. Of the sample, 360 mg/day orlistat as an adjuvant therapy, was administered to overweight or obese T2DM patients together with hypocaloric intake (8 studies) or without hypocaloric intake (1 study) intervention. They were examined for 12-52 weeks. From 2 short-term (12 weeks) studies, one study revealed that orlistat improved HbA1c and fasting plasma glucose (FPG) level significantly, while one study showed no significant effect compared to placebo. Seven other studies (long term observation) had found that orlistat significantly improved HbA1c and FPG level. All studies found that orlistat significantly reduced body weight. As an adjuvant therapy, Orlistat improved HbA1c and FPG level in overweight and obese T2DM patients. 

Keywords

Orlistat type 2 diabetes mellitus overweight obesity glycemic control body weight

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Johan, A. R. D., Dewanti, L., Putri, A. N., Pantoro, B. I., Albab, C. F., Hutauruk, M. M. D., & Novitasari, T. (2022). The Effect of Orlistat Administration in Change of Glycemic Control and Weight Loss of Obesity or Overweight Patients with Type 2 Diabetes Mellitus. Folia Medica Indonesiana, 58(1), 74–79. https://doi.org/10.20473/fmi.v58i1.26752
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Aldekhail N, Logue J, McLoone P, et al (2015). Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Obes. Rev. 16, 1071–1080.
  2. Bhupathiraju S, Hu F (2016). Epidemiology of obesity and diabetes and their cardiovascular complications. Circ. Res. 118, 1723–1735.
  3. Chauhan S, Arnold K, Mackenzie C, et al (2011). The influence of Orlistat (Xenical®) on weight loss in overweight and obese adults: a systematic review. In: Proceedings of the Nutrition Society. p. e18.
  4. Derosa G, Cicero A, D’Angelo A, et al (2011). Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J. Clin. Pharm. Ther. 37, 187–195.
  5. Hanefield M, Sachse G (2002). The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes, Obes. Metab. 4, 415–423.
  6. Jacob S, Rabbia M, Meier M, et al (2009). Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes, Obes. Metab. 11, 361–371.
  7. Jain S, Ramanand S, Ramanand J, et al (2011). Evaluation of efficacy and safety of orlistat in obese patients. Indian J. Endocrinol. Metab. 15, 99–104.
  8. Kelley D, Kuller L, McKolanis T, et al (2003). Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27, 33–40.
  9. Kopelman P, de Groot H, Rissanen A, et al (2010). Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: Comparison with orlistat (Xenical). Obesity 18, 108–115.
  10. Kumanyika S, Jeffery R, Morabia A, et al (2002). Obesity prevention: The case for action. Int. J. Obes. 26, 425–436.
  11. Kuo C, Pei D, Yao C, et al (2006). Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract. 60, 906–910.
  12. Rowe R, Cowx M, Poole C, et al (2005). The effects of orlistat in patients with diabetes: Improvement in glycaemic control and weight loss. Curr. Med. Res. Opin. 21, 1885–1890.
  13. Shi Y, Pan C, Hill J, et al (2005). Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabet. Med. 22, 1737–1743.
  14. Wannamethee S, Shaper A (1999). Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 22, 1266–1272.
  15. Williamson D, Thompson T, Thun M, et al (2000). Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23, 1499–1504.